Pharsight

Femtrace patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6962908 APIL Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Dec, 2021

(2 years ago)

US7799771 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Dec, 2021

(2 years ago)

US7572779 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Oct, 2025

(1 year, 3 months from now)

Femtrace is owned by Apil.

Femtrace contains Estradiol Acetate.

Femtrace has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Femtrace are:

  • US6962908
  • US7799771

Femtrace was authorised for market use on 20 August, 2004.

Femtrace is available in tablet;oral dosage forms.

Femtrace can be used as treatment of moderate to severe vasomotor symptoms associated with menopause.

The generics of Femtrace are possible to be released after 02 October, 2025.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ESTRADIOL ACETATE ingredient

Market Authorisation Date: 20 August, 2004

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage

FEMTRACE family patents

Family Patents